top of page
🔹 FDA & Regulatory Guidance
OPDP Untitled Letters Archive
Examples of promotional violations since 1997
FDA AI in Regulatory Decision-Making – Draft Guidance (2025)
Covers AI validation, transparency, data integrity, and human oversight in submissions
CDER AI for Drug Development Hub
FDA resource on AI use across the drug lifecycle
🔹 Peer-Reviewed & Academic Literature
Global GMP & AI Frameworks
Analysis of FDA/EMA/WHO perspectives on AI validation, ethics, and audit trails
AI Across the Drug Lifecycle
Explores AI’s role in clinical development, regulatory approvals, and post-market surveillance
Comparative AI Regulation: US, EU, Global
Highlights evolving international frameworks
🔹 Market Access, HTA & Real-World Evidence
Real-World Evidence for Payers
Barriers to RWE adoption by payers
Intro to HTA & Cost-Effectiveness
Covers QALY, decision thresholds, and global HTA methodology
Accelerated Device Approvals: FDA vs. EU
Comparison of BDP, TCET, MDR pathways (relevant to medtech market entry strategy
🔹 RWE in Action
RWE in Clinical Trials (Quanticate)
Case examples of label expansions using RWE
.
The REVEAL Study
Review of RWE integration in pre-marketing strategies
🔹 Digital Health & AI Adoption Barriers
Clinician Barriers to Digital Health
Systematic review of adoption hurdles
Adoption Friction in Health Tech
Explores reimbursement blockers, and value-based care misalignment
🔹 AI & Compliance Whitepapers
AI in Regulatory Affairs & QA (IQVIA)
Covers automation in submissions and QA
AI in Market Access (Eularis)
How AI enables faster, evidence-led pricing and reimbursement decisions
AI in PRMA (Life Sciences Dynamics)
Tracks emerging AI applications in pricing and reimbursement strategy
Market Access Analytics (Intuition Labs)
Overview of scenario modeling, NLP, and advanced analytics for payer negotiation
🔹 Commercialization & Go-To-Market
Commercialization Framework (LinkedIn)
Step-by-step roadmap from R&D through GTM, tailored for medtech and biotech firms
Biotech Launch Case Study (Flevy)
Details launch acceleration and market share growth via regulatory optimization
EndemicEase Vaccine Regulatory Walkthrough
Real-world IND-to-approval blueprint
Selling Into Hospitals (Storm Ventures)
Practical GTM strategy for healthtech/medtech
🔹 Patent & Lifecycle Strategy
Patent Cliff Strategy (PMC)
Outlines extension tactics
The Patent Cliff Playbook
Advanced guide to exclusivity loss management, biosimilars, and litigation
🔹 VC & Funding Trends
2024–2025 VC Reports: Health Tech & AI
HSBC, Paragon, Rock Health, and others on AI-health deal flow and Series B gaps
AI Biotech Mega-Rounds (Intuition Labs)
Analysis of capital-efficient biotech models and team structures
Canada Life Sciences VC Landscape (DEEP Centre)
Outlines funding bottlenecks and scaling pathways in the Canadian ecosystem
🔹 Sectoral Insights & Policy
McKinsey: AI in Payer Transformation
How payers can capture $150M+ in cost savings via AI
Health Technology Assessment (HTA) Primer
Foundational guide to HTA principles and global application
bottom of page